Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

In a letter sent to hospitals and clinics on Friday, Sanofi indicated that certain hospitals covered by the 340B Drug ...